Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Top Cited Papers
Open Access
- 10 January 2019
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
Abstract
PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation. Many potent PROTACs with specificity for dissimilar targets have been developed; however, the factors governing degradation selectivity within closely-related protein families remain elusive. Here, we generate isoform-selective PROTACs for the p38 MAPK family using a single warhead (foretinib) and recruited E3 ligase (von Hippel-Lindau). Based on their distinct linker attachments and lengths, these two PROTACs differentially recruit VHL, resulting in degradation of p38α or p38δ. We characterize the role of ternary complex formation in driving selectivity, showing that it is necessary, but insufficient, for PROTAC-induced substrate ubiquitination. Lastly, we explore the p38δ:PROTAC:VHL complex to explain the different selectivity profiles of these PROTACs. Our work attributes the selective degradation of two closely-related proteins using the same warhead and E3 ligase to heretofore underappreciated aspects of the ternary complex model.Keywords
This publication has 70 references indexed in Scilit:
- Kinase inhibitors: the road aheadNature Reviews Drug Discovery, 2018
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?Journal of Medicinal Chemistry, 2017
- Targeted Protein Degradation: from Chemical Biology to Drug DiscoveryCell Chemical Biology, 2017
- Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic StrategyACS Chemical Biology, 2017
- p38γ and p38δ Mitogen Activated Protein Kinases (MAPKs), New Stars in the MAPK GalaxyFrontiers in Cell and Developmental Biology, 2016
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4Chemistry & Biology, 2015
- p38MAPK: stress responses from molecular mechanisms to therapeuticsTrends in Molecular Medicine, 2009
- Inhibition of p38: Has the fat lady sung?Arthritis & Rheumatism, 2009
- What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical TrialsJournal of Clinical Oncology, 2006
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005